AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03856632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RFM
Description: The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
Study NCT03856632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti Arrhythmics
Description: The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
Study NCT03856632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti Arrhythmics
Description: The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
Study NCT03856632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Afib Catheter Ablation
Description: The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
Study NCT03856632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Afib Catheter Ablation
Description: The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
Study NCT01264328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab + paclitaxel
Description: Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
Study NCT03763539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy
Study NCT00301925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT01068327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01068327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01068327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Description: Given PO
Study NCT01068327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo radiotherapy
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00301925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00301925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00301925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Study NCT04551859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Pelvic Floor MRI
Description: 6 months after surgery, a Dynamic Pelvic Floor MRI is performed
Study NCT00967707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin and venlafaxine
Description: Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added.
Study NCT00967707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin and donepezil
Description: Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added.
Study NCT03065517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VillageWhere App
Description: VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
Study NCT03065517 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Attention-Control Placebo App
Description: Mobile phone app for use on both Android and iOS platforms.
Study NCT04344782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Treatment includes the administration on day 1 (D1) of an infusion of Bevacizumab 7.5 mg / kg in 100 ml saline for all patients weighing 100 kg or more. In control arm, patient receives standard care.
Study NCT03032237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention - protein-rich
Description: Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks.
Study NCT03032237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention - standard
Description: Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks.
Study NCT02822612 — intervention group
Intervention type: DEVICE
Intervention: Binocular OCT prototype
Description: Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
Study NCT01068327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Undergo radiotherapy
Study NCT01068327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT04893889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Shear-wave elastography
Description: Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
Study NCT04893889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography
Description: Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
Study NCT04893889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Shear-wave elastography
Description: Myocardial shear wave elastography to assess myocardial stiffness by non-invasively quantifying diastolic myocardial elasticity.
Study NCT03615651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
Study NCT03615651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention.
Study NCT00210652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ 333369:
Description: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
Study NCT03839667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive diet intervention
Description: the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
Study NCT03839667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity intervention
Description: the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
Study NCT03839667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education
Description: the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
Study NCT02104557 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study NCT03939728 — intervention group
Intervention type: RADIATION
Intervention: Chest radiography and lung ultrasound
Description: We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
Study NCT01311505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrin© 2 (Rifampicin + Isoniazid)
Description: Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
Study NCT02507102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voyager
Description: Non-invasive RFE therapy
Study NCT01311505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimactane® (Rifampicin)
Description: One (1) capsule of Rifampicin 300 mg
Study NCT00585754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: 1.5mg BID
Study NCT00585754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02960880 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY597939)
Description: 15mg, 20mg
Study NCT02960880 — intervention group
Intervention type: DRUG
Intervention: Phenprocoumon (branded and generics)
Description: Individually adjusted dose
Study NCT00801684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
Study NCT00801684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2D
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study NCT00801684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2SS
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study NCT00801684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2D
Description: Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study NCT00801684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TrIP-2SS + Foradil
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Study NCT02468843 — intervention group
Intervention type: DEVICE
Intervention: Biphasic DBS stimulation
Description: The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes~3. Biphasic pulse stimulation mode (immediate assessment)~4. Biphasic pulse stimulation mode (assessment at 1h)~5. Biphasic pulse stimulation mode (assessment at 2h)
Study NCT02468843 — intervention group
Intervention type: OTHER
Intervention: Unified Dystonia Rating Scale
Description: Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
Study NCT02468843 — intervention group
Intervention type: OTHER
Intervention: Burke-Fahn- Marsden scale
Description: Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
Study NCT03611634 — intervention group
Intervention type: OTHER
Intervention: BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE
Description: collection of saddles
Study NCT01727531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate
Description: 250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
Study NCT03666598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
Study NCT03797027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy without an abdominal cushion
Description: patients undergo prone PNCL without an abdominal cushion
Study NCT03797027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy with an 5 cm abdominal cushion
Description: patients undergo prone PNCL with an 5 cm abdominal cushion
Study NCT03797027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous Nephrolithotomy with an 5 cm abdominal cushion
Description: patients undergo prone PNCL with an 10 cm abdominal cushion
Study NCT05447988 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Breast Tissue Expander
Description: tissue expander based breast reconstruction
Study NCT00301873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Zometa
Description: Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
Study NCT01764594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP7657
Description: CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks
Study NCT01764594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT00928785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REPEVAX
Description: 1 dose of 0.5 mL at Day 0
Study NCT00928785 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Tetanus vaccine
Description: 1 dose of 0.5 mL at Day 0
Study NCT02801201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT02801201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02175472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectramax light therapy device
Description: Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
Study NCT02175472 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control light device
Description: The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
Study NCT02122744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super Rapid Magstim Stimulator
Description: The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil.
Study NCT02122744 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Super Rapid Magstim Stimulator (sham)
Description: coil perpendicular to the scalp
Study NCT02611531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Module Education (VME)
Description: Participants will complete inhaler education on a tablet device
Study NCT02611531 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teach-To-Goal (TTG)
Description: Participants will complete intensive in-person inhaler education
Study NCT01518296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic-Dantec Urodynamic System
Description: Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
Study NCT04062643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Obesity assessment
Description: Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
Study NCT00317031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate or Naltrexone
Description: mg\&d 90 days
Study NCT00317031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acamprosate or Naltrexone
Description: mg\&d 90 days
Study NCT02352207 — intervention group
Intervention type: OTHER
Intervention: identification of a pulmonary malformation in the fetus
Study NCT01353794 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
Study NCT02996604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
Study NCT02996604 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
Study NCT03487913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist
Study NCT02633475 — intervention group
Intervention type: GENETIC
Intervention: IL-10 polymorphism
Description: The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
Study NCT02875106 — intervention group
Intervention type: DEVICE
Intervention: 12-point-ECG
Description: routine recording will be 300 seconds
Study NCT02875106 — intervention group
Intervention type: DEVICE
Intervention: Polar V800
Description: routine recording will be 300 seconds
Study NCT02875106 — intervention group
Intervention type: DEVICE
Intervention: 360° eMotion FAROS SET + Belt
Description: routine recording will be 300 seconds
Study NCT02875106 — intervention group
Intervention type: DEVICE
Intervention: Adidas Micoach smart run
Description: routine recording will be 300 seconds